Study links phosphate levels to kidney damage markers
Researchers at University of Tsukuba have found that the phosphate concentration in proximal tubule fluid, estimated from ...
Le Lézard1d
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Tharimmune, Inc. ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of ...
Ipsen Pharma: Iqirvo (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 202 ...
manilatimes4d
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
No new safety findings were observed. The most common treatment-emergent adverse events (>10 percent) occurring more ...
ThePrint4d
“Respiratory disease cases are doubled in hospitals and affecting every age group,” say experts
The Air Quality Index (AQI) remains severe to hazardous in Delhi NCR which is a leading cause of the rise in respiratory and chest infection cases in hospitals. According to Dr Sudhir Gupta, senior ...
FDA Recalls Chronic Kidney Disease Medication Over Impurity Concerns
Nearly 300,000 bottles of the drug, named Cinacalcet, were recalled and given a Class II recall risk level by the FDA.